ProShare Advisors
TYRA icon

ProShare Advisors’s Tyra Biosciences TYRA Stock Holding History

ProShare Advisors’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Buy
6,765
+623
+10% +$20.6K ﹤0.01% 1598
2026
Q1 		$235K Buy
+6,142
New +$199K ﹤0.01% 1476

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

ProShare Advisors's TYRA Position: Q2 2026 in Review

ProShare Advisors increased its Tyra Biosciences (TYRA) stake by 10% in Q2 2026, buying an estimated $20.6K and bringing the position to 6,765 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1598.

ProShare Advisors first reported a position in TYRA in Q1 2026 and has held it in 2 quarters since. The position peaked at $235K in Q1 2026. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • ProShare Advisors held 6,765 shares of Tyra Biosciences worth $216K as of Q2 2026.
  • ProShare Advisors bought 623 Tyra Biosciences shares in Q2 2026, an estimated $20.6K.
  • Tyra Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1598 holding.
  • ProShare Advisors first reported a position in Tyra Biosciences in Q1 2026 and has held it in 2 quarters since.
  • ProShare Advisors's Tyra Biosciences position peaked at $235K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.